Bioxcel Therapeutics (BTAI) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $6.00 | Apr 2, 2026 |
| Rodman & Renshaw | Initiated Coverage | Buy | $17.00 | Mar 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $6.00 from $10.00 | Mar 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Sep 15, 2025 |
| Mizuho | Maintained | Neutral | $4.00 from $2.00 | Sep 12, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Aug 28, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Aug 19, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $8.00 | Aug 15, 2025 |
| LUCID CAPITAL MARKETS | Maintained | Buy | $66.00 | Jul 15, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $8.00 from $3.00 | Jun 23, 2025 |
| Rodman & Renshaw | Initiated Coverage | Buy | $65.00 | Mar 19, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $3.00 from $5.00 | Jan 30, 2025 |
| B of A Securities | Downgraded | Buy → Underperform | $0.25 from $7.00 | Jan 7, 2025 |
| Canaccord Genuity | Maintained | Buy | $5.00 from $7.00 | Jan 6, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $5.00 from $7.00 | Oct 21, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 | Sep 6, 2024 |
| Canaccord Genuity | Maintained | Buy | $7.00 | Aug 30, 2024 |
| UBS | Maintained | Neutral | $1.00 from $3.50 | Aug 9, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $7.00 from $10.00 | Aug 8, 2024 |
| Canaccord Genuity | Maintained | Buy | $7.00 | Jun 27, 2024 |
Frequently asked questions
Is BTAI a buy, sell, or hold?
Analysts covering Bioxcel Therapeutics currently average a Sell rating: 0 buy, 0 hold and 1 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on BTAI?
On Apr 2, 2026, HC Wainwright & Co. maintained Bioxcel Therapeutics at Buy with a price target of $5.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.